Skip to main content
Addgene

pAd388-BPTF-sh28
(Plasmid #83276)

Print

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 83276 Standard format: Plasmid sent in bacteria as agar stab 1 $85 *
Add to Cart

* Log in to view industry pricing.

Backbone

  • Vector backbone
    pAd388
  • Backbone manufacturer
    OD260 Inc
  • Backbone size w/o insert (bp) 36741
  • Total vector size (bp) 38638
  • Modifications to backbone
    DraIII digested cos from pE3.1 and DraIII digested expression cassette + Kan resistance from pE1.2 were ligated into SfiI digested pAd388
  • Vector type
    Adenoviral

Growth in Bacteria

  • Bacterial Resistance(s)
    Kanamycin, 50 μg/mL
  • Growth Temperature
    30°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    shRNA to BPTF
  • gRNA/shRNA sequence
    Bptf
  • Species
    H. sapiens (human), M. musculus (mouse)
  • Promoter pUC ori

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site BamHI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer ?
    • (Common Sequencing Primers)

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pAd388-BPTF-sh28 was a gift from Joe Landry (Addgene plasmid # 83276 ; http://n2t.net/addgene:83276 ; RRID:Addgene_83276)

  • For your References section:

    BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. Mayes K, Elsayed Z, Alhazmi A, Waters M, Alkhatib SG, Roberts M, Song C, Peterson K, Chan V, Ailaney N, Malapati P, Blevins T, Lisnic B, Dumur CI, Landry JW. Oncotarget. 2017 May 12;8(38):64344-64357. doi: 10.18632/oncotarget.17834. eCollection 2017 Sep 8. 10.18632/oncotarget.17834 PubMed 28969075
Related items: